Biomarkers · Cardiometabolic
Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)
Lower values go with lower risk of death. No risk curve catalogued yet.
Published risk of death1.40×3rd vs 1st tertile of LpPLA2 concentration (>=475 vs <=307 ng/mL), adjusted (95% CI 1.15–1.71) · LURIC: patients scheduled for coronary angiography, 2298 with and 661 without angiographic CAD, Germany
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in Lp-PLA2, study by study
2 effects with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| pharmacologic | Statin treatment vs placebo (10 RCTs) on lipoprotein-associated phospholipase A2 activity | Lp-PLA2 activity WMD -39.37 nmol/min/mL (95% CI -69.99 to -8.75); mass -44.46 ng/mL | meta-analysis | Sahebkar A, et al. Cardiovasc Drugs Ther. 2025. Effect of Statin Treatment on… |
| pharmacologic | Pitavastatin 4 mg daily for 52 weeks in ART-treated adults with HIV and dyslipidemia | Lp-PLA2 -26.6% with pitavastatin vs -15.5% with pravastatin at week 52 (p=0.005) | RCT | Toribio M, et al. AIDS. 2017. Effects of pitavastatin and pravastatin on… |
What else moves this marker
They describe those study groups, not an individual, and an association is not a cause.
Diseases and conditions
| What | Effect on the marker | Comparison · population | Source |
|---|---|---|---|
| ↑ Premature ST-elevation myocardial infarction (age <50) · young STEMI patients vs healthy controls | ratio 1.71 | young STEMI patients (5.97 +/- 1.39 ng/mL) vs healthy controls (3.49 +/- 1.27 ng/mL) · 110 STEMI patients aged 18-50 years and 110 healthy controls, India | case control · PMID 36574567 |
Genetic predisposition
| What | Effect on the marker | Comparison · population | Source |
|---|---|---|---|
| ↑ PLA2G7 rs1805017 · per allele effect on Lp-PLA2 mass | +0.043 log(Lp-PLA2 mass) units per allele | per copy of the rs1805017 allele · 13,664 participants of five community-based cohorts (CHARGE Consortium) | gwas · PMID 22003152 |
| ↓ rs4420638 near the APOE-APOC1-APOC4-APOC2 cluster · per allele effect on Lp-PLA2 activity | -0.054 log(Lp-PLA2 activity) units per allele | per copy of the rs4420638 allele · 13,664 participants of five community-based cohorts (CHARGE Consortium) | gwas · PMID 22003152 |